Gentian USA Inc
Gentian’s goal is to increase efficiency and decrease costs associated with human and veterinary diagnostic testing in areas of kidney, infectious, inflammatory, and cardiovascular diseases. In combining 20+ years of industry experience with proprietary technologies, Gentian has established itself as a leader in Particle-Enhanced Turbidimetric Immunoassay (PETIA) development. The current product portfolio includes cystatin C (510(k)-cleared/CE marked), plasma and serum calprotectin (CE marked/US Research Use Only), canine CRP and fecal calprotectin assays. Gentian also welcomes opportunities for collaboration with OEMs.
Gentian products can be used without additional investment in instrumentation because assays are designed for use on all major clinical chemistry analyzers. Production, R&D, marketing and distribution of immunoassays are performed at our headquarters in Norway and are supported globally by subsidiaries in the US and Sweden and a representative office in China.
Additional Info
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth?
No